Sobi CEO invests in 2015 LTI programme and divests a portion of incentive shares
On 25 September Swedish Orphan Biovitrum AB (publ)'s (Sobi) CEO Geoffrey McDonough purchased 34,000 Sobi shares as part of the company's 2015 CEO long-term incentive programme. The programme requires that the CEO make an investment in common shares in Sobi for an amount of 4 MSEK which are subject to a 3 year lock-up period.
Geoffrey McDonough also divested 78,500 of the shares he holds in Sobi. The sale was made in order to cover the estimated US tax due for the company's 2012 long-term incentive programme which vested in June 2015. The CEO now holds a total of 774,923 shares in the company.
Terms and conditions of the Sobi 2015 CEO long-term incentive program can be found on www.sobi.com.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|